Payment overview · 2025
General Payments
$447.01
23 reported records · 11 companies
Healthcare provider profile · identity verified
Jonathan Baza, DO
Allopathic & Osteopathic Physicians|Family Medicine · LUMBERTON, NC · NPI 1861840803
Verified facts
What the public records show
CMS Open Payments records show Jonathan Baza, DO received $447.01 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.94 | 19.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $84.05 | 18.8% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $50.69 | 11.3% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $49.09 | 11.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.17 | 9.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.16 | 8.5% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $21.29 | 4.8% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $20.22 | 4.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.86 | 4.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.62 | 3.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.92 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $447.01 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $68.99 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $54.51 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.55 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $50.69 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $49.09 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $42.17 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.17 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.54 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $16.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 534 | 159 |
| Atorvastatin Calcium | Atorvastatin Calcium | 366 | 119 |
| Lisinopril | Lisinopril | 239 | 73 |
| Omeprazole | Omeprazole | 237 | 84 |
| Losartan Potassium | Losartan Potassium | 233 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 226 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 64 |
| Metformin Hcl | Metformin Hcl | 182 | 52 |
| Gabapentin | Gabapentin | 161 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 51 |
| Simvastatin | Simvastatin | 137 | 36 |
| Trazodone Hcl | Trazodone Hcl | 134 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 49 |
| Alprazolam | Alprazolam | 126 | 44 |
| Potassium Chloride | Potassium Chloride | 116 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 47 |
| Liothyronine Sodium | Liothyronine Sodium | 107 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 37 |
| Finasteride | Finasteride | 98 | 33 |
| Tramadol Hcl | Tramadol Hcl | 94 | 34 |
| Prednisone | Prednisone | 93 | 73 |
| Sertraline Hcl | Sertraline Hcl | 92 | 24 |
| Furosemide | Furosemide | 91 | 37 |
| Montelukast Sodium | Montelukast Sodium | 91 | 30 |
| Spironolactone | Spironolactone | 87 | 24 |
| Carvedilol | Carvedilol | 85 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 17 |
| Lorazepam | Lorazepam | 72 | 22 |
| Bupropion Xl | Bupropion Hcl | 71 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 32 |
| Azithromycin | Azithromycin | 69 | 62 |
| Clonazepam | Clonazepam | 67 | 13 |
| Eliquis | Apixaban | 67 | 25 |
| Diazepam | Diazepam | 66 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 22 |
| Temazepam | Temazepam | 64 | 16 |
| Celecoxib | Celecoxib | 63 | 23 |
| Metformin Hcl Er | Metformin Hcl | 63 | 19 |
| Meloxicam | Meloxicam | 62 | 22 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 51 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 16 |
| Atenolol | Atenolol | 48 | 14 |
| Warfarin Sodium | Warfarin Sodium | 48 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 11 |
| Allopurinol | Allopurinol | 46 | 17 |
| Famotidine | Famotidine | 46 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 17 |
| Estradiol | Estradiol | 44 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 13 |
| Xarelto | Rivaroxaban | 44 | 13 |
| Pregabalin | Pregabalin | 42 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 32 |
| Fluconazole | Fluconazole | 35 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 15 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 11 |
| Baclofen | Baclofen | 33 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 12 |
| Valacyclovir | Valacyclovir Hcl | 32 | 18 |
| Sucralfate | Sucralfate | 31 | 14 |
| Cefdinir | Cefdinir | 30 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 19 |
| Progesterone | Progesterone, Micronized | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 21 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | 14 |
| Nystatin | Nystatin | 20 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Topiramate | Topiramate | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 15 |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 11 |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Imipramine Pamoate | Imipramine Pamoate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Telmisartan | Telmisartan | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $447.01 · 23 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, COMIRNATY, EVENITY, FARXIGA, Flector, General - Pain Management, INSPIRE, JARDIANCE, KRYSTEXXA, Licart, MINIMED 780G, NEXPLANON, PREVNAR 20, Prolastin-C Liquid, QULIPTA, Tirosint, UBRELVY, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error